Friday, 13 Jul 2018

You are here

T2T Improves Primary Care Gout Management

Researchers from Geisinger Medical center tested a pilot primary care gout management improvement intervention, and demonstrated significantly improved primary care gout management metrics when a treat to target approach was implemented. 

They studied 2 large primary care sites - one underwent the intervention, the other/control, did not. The gout management plan ("intervention") included education of the intervention staff and EMR to assess outcomes; 1) percent of gout patients treated with urate lowering therapy; 2) percent of treated patients monitored with serum urate; and 3) percent of treated patients at target serum urate ≤ 6.0 mg/dl. The intervention site providers received monthly performance reports compared to their peers.

At 6 months, the intervention site significantly improved all 3 gout performance measures.

  • ULT use increased from 54.4 to 61.1%, OR 1.19 (95% CI 1.08, 1.31 and p-value <0.001);
  • Monitoring increased from 56.1 to 79.2% OR 1.52 (95% CI 1.24, 1.87 and P-value <0.001);
  • Achieving a T2T goal (< 6.0)  increased from 26.8 to 43.3% OR 1.43 (95% CI 1.16, 1.77 and p-value <0.001.

At 6 months gout patients at the intervention site were 3.5 times more likely to be monitored and 2 times more likely to achieve their urate goal (p-value <0.001) than control site patients.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Obesity, Hypertension and Diuretics Drive Gout Risk

A recent metanalysis suggests that obesity, hypertension and diuretic use are associated with a two-fold increased risk of incident gout.

From a potential of 9923 articles, researchers analyzed 11 studies with data suitable for the meta-analysis.

Gout was 2.24 times more likely to occur in individuals with body mass index ≥ 30 kg/m2 (adjusted relative risk 2.24 (95% confidence interval) 1.76–2.86).

Public Citizen Pressures FDA to Pull Febuxostat

Public Citizen has petitioned the U.S. Food and Drug Administration (FDA) to remove Takeda's drug febuxostat (Uloric) from the market, citing the FDA's own warnings and evidence of serious cardiovascular harms. This follows on a recent FDA safety warning and NEJM paper citing cardiovascular concerns over febuxostat.

Gout Takeaways

The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.

Sons of Gout Study

The genetics and heritability of gout has suggested a higher risk in certain families.  A UK cohort study examined the prevalence of gout and monosodium urate (MSU) crystal deposition among those at risk (sons of gout patients) for gout and found a high incidence of hyperuricemia and MSU crystal deposition.

The Hazardous Highs and Lows of Uric Acid

Both high and low levels of uric acid were linked with increased risks of death, showing a U-shaped association between serum uric acid levels and all-cause, cardiovascular, and cancer mortality, Korean researchers reported.